Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Oliceridine (Olinvyk) is indicated for the management of acute pain severe enough to require an intravenous opioid analgesic in adults, particularly when alternative treatments are inadequate.
• Two studies affirmed that Oliceridine effectively manages acute postoperative pain, and its proportion of treatment responders was comparable to morphine, a standard for evaluating new analgesic medications due to its well-established efficacy profile.
• The safety profile of Oliceridine shows a reduced incidence of respiratory safety events compared to morphine. This suggests an improved safety profile, especially concerning opioid-related adverse events (ORAEs).
• There is increased nausea and vomiting associated with Oliceridine use compared to placebo. Despite these gastrointestinal side effects, its ability to provide effective pain management with a lower risk of severe ORAEs may justify its use.
• One study suggested a potential role for Oliceridine within multimodal analgesia strategies due to its novel pharmacological advantage of minimizing opioid usage while effectively managing pain. This aligns with current trends seeking a balance between efficacy and safety amidst the ongoing opioid epidemic.
• Neither study provided detailed information on specific population types or subgroup considerations beyond the adult population experiencing acute postoperative pain. Future research could benefit from exploring the drug’s effectiveness across diverse patient subgroups, including those with varying degrees of severity, different surgical procedures, and patient comorbidities.